Back to Search
Start Over
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection
- Source :
- FRONTIERS IN ONCOLOGY, Scientia, Infante, M S, Salmanton-García, J, Fernández-Cruz, A, Marchesi, F, Jaksic, O, Weinbergerová, B, Besson, C, Duarte, R F, Itri, F, Valković, T, Szotkovski, T, Busca, A, Guidetti, A, Glenthøj, A, Collins, G P, Bonuomo, V, Sili, U, Seval, G C, Machado, M, Cordoba, R, Blennow, O, Abu-Zeinah, G, Lamure, S, Kulasekararaj, A, Falces-Romero, I, Cattaneo, C, van Doesum, J, Piukovics, K, Omrani, A S, Magliano, G, Ledoux, M-P, de Ramon, C, Cabirta, A, Verga, L, López-García, A, da Silva, M G, Stojanoski, Z, Meers, S, Lahmer, T, Martín-Pérez, S, Dávila-Vals, J, van Praet, J, Samarkos, M, Bilgin, Y M, Karlsson, L K, Batinić, J, Nordlander, A, Schönlein, M, Hoenigl, M, Ráčil, Z, Mladenović, M, Hanakova, M, Zambrotta, G P M, de Jonge, N, Adžić-Vukičević, T, Nunes-Rodrigues, R, Prezioso, L, Navrátil, M, Marchetti, M, Cuccaro, A, Calbacho, M, Giordano, A, Cornely, O A, Hernández-Rivas, J-Á & Pagano, L 2022, ' B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection : A European Hematology Association Survey (EPICOVIDEHA) ', Frontiers in Oncology, vol. 12, 992137 . https://doi.org/10.3389/fonc.2022.992137, Frontiers in Oncology, 12:992137. Frontiers Media SA, Frontiers in Oncology, 12:992137. Frontiers Media S.A., Infante, M S, Salmanton-García, J, Fernández-Cruz, A, Marchesi, F, Jaksic, O, Weinbergerová, B, Besson, C, Duarte, R F, Itri, F, Valković, T, Szotkovski, T, Busca, A, Guidetti, A, Glenthøj, A, Collins, G P, Bonuomo, V, Sili, U, Seval, G C, Machado, M, Cordoba, R, Blennow, O, Abu-Zeinah, G, Lamure, S, Kulasekararaj, A, Falces-Romero, I, Cattaneo, C, Van Doesum, J, Piukovics, K, Omrani, A S, Magliano, G, Ledoux, M-P, de Ramon, C, Cabirta, A, Verga, L, López-García, A, Da Silva, M G, Stojanoski, Z, Meers, S, Lahmer, T, Martín-Pérez, S, Dávila-Vals, J, Van Praet, J, Samarkos, M, Bilgin, Y M, Karlsson, L K, Batinić, J, Nordlander, A, Schönlein, M, Hoenigl, M, Ráčil, Z, Mladenović, M, Hanakova, M, Zambrotta, G P M, De Jonge, N, Adžić-Vukičević, T, Nunes-Rodrigues, R, Prezioso, L, Navrátil, M, Marchetti, M, Cuccaro, A, Calbacho, M, Giordano, A, Cornely, O A, Hernández-Rivas, J Á & Pagano, L 2022, ' B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection : A European Hematology Association Survey (EPICOVIDEHA) ', Frontiers in Oncology, vol. 12, 992137 . https://doi.org/10.3389/fonc.2022.992137, Frontiers in Oncology, Volume 12
- Publication Year :
- 2022
-
Abstract
- Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<br />EPICOVIDEHA has received funds from Optics COMMITTM (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223).
- Subjects :
- Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT]
Internal Diseases
Cancer Research
SARS-CoV-2
chronic lymphocytic leukemia (CLL)
immune system COVID19
infection risk
lymphoproliferative diseases (LPD)
non-Hodgkin lymphoma (NHL)
targeted drugs
Sağlık Bilimleri
COVID-19 (Malaltia)
İç Hastalıkları
Clinical Medicine (MED)
BİYOKİMYA VE MOLEKÜLER BİYOLOJİ
virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES]
Medicine and Health Sciences
IDELALISIB
Klinik Tıp (MED)
03.02. Klinikai orvostan
IBRUTINIB
BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina
Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders [DISEASES]
RNA COVID-19 VACCINE
BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Oncology
Klinik Tıp
OBINUTUZUMAB
CHALLENGES
Temel Bilimler
Life Sciences
Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES]
Onkoloji
ddc
Tıp
MOLECULAR BIOLOGY & GENETICS
Oncology
CHLORAMBUCIL
Medicine
ONKOLOJİ
Natural Sciences
BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Infektologija
Life Sciences & Biomedicine
BIOCHEMISTRY & MOLECULAR BIOLOGY
Sitogenetik
Life Sciences (LIFE)
Molecular Biology and Genetics
Enquestes
Yaşam Bilimleri
Health Sciences
Trastorns limfoproliferatius
Cytogenetic
RITUXIMAB
BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine
Moleküler Biyoloji ve Genetik
Science & Technology
Internal Medicine Sciences
CHRONIC LYMPHOCYTIC-LEUKEMIA
técnicas de investigación::métodos epidemiológicos::recopilación de datos::encuestas y cuestionarios [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS]
Dahili Tıp Bilimleri
CLINICAL MEDICINE
BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Infectology
enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos [ENFERMEDADES]
ONCOLOGY
EFFICACY
Settore MED/15 - MALATTIE DEL SANGUE
Yaşam Bilimleri (LIFE)
BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Onkologija
Kanser Araştırmaları
Subjects
Details
- Language :
- English
- ISSN :
- 2234943X
- Volume :
- 12
- Database :
- OpenAIRE
- Journal :
- Frontiers in Oncology
- Accession number :
- edsair.doi.dedup.....0771f06a4f47e25b7d01121c58843cdc
- Full Text :
- https://doi.org/10.3389/fonc.2022.992137